These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23719231)

  • 1. Structure-activity relationship studies and sleep-promoting activity of novel 1-chloro-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 2.
    Sifferlen T; Koberstein R; Cottreel E; Boller A; Weller T; Gatfield J; Brisbare-Roch C; Jenck F; Boss C
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3857-63. PubMed ID: 23719231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, structure-activity relationship studies, and identification of novel 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 1.
    Sifferlen T; Koberstein R; Cottreel E; Boller A; Weller T; Gatfield J; Brisbare-Roch C; Jenck F; Boss C
    Bioorg Med Chem Lett; 2013 Apr; 23(7):2212-6. PubMed ID: 23434414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of substituted lactams as novel dual orexin receptor antagonists. Synthesis, preliminary structure-activity relationship studies and efforts towards improved metabolic stability and pharmacokinetic properties. Part 1.
    Sifferlen T; Boller A; Chardonneau A; Cottreel E; Hoecker J; Aissaoui H; Williams JT; Brotschi C; Heidmann B; Siegrist R; Gatfield J; Treiber A; Brisbare-Roch C; Jenck F; Boss C
    Bioorg Med Chem Lett; 2014 Feb; 24(4):1201-8. PubMed ID: 24447850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.
    Sifferlen T; Boller A; Chardonneau A; Cottreel E; Gatfield J; Treiber A; Roch C; Jenck F; Aissaoui H; Williams JT; Brotschi C; Heidmann B; Siegrist R; Boss C
    Bioorg Med Chem Lett; 2015 May; 25(9):1884-91. PubMed ID: 25838147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure activity relationship studies of imidazo[1,2-a]pyrazine derivatives against cancer cell lines.
    Myadaraboina S; Alla M; Saddanapu V; Bommena VR; Addlagatta A
    Eur J Med Chem; 2010 Nov; 45(11):5208-16. PubMed ID: 20832916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [SCA 40 and derivatives: new bronchodilators in an imidazo(1,2-a)pyrazine series].
    Bonnet PA; Vitse O; Bénezech V; Subra G; Fabréguettes JR; Zanik L; Laurent F; Michel A; Bompart J; Chapat JP
    Ann Pharm Fr; 1998; 56(4):155-9. PubMed ID: 9770008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of pyridazinone derivatives bearing tetrahydroimidazo[1,2-a]pyrazine scaffold as potent inhibitors of transient receptor potential canonical 5 to ameliorate hypertension-induced renal injury in rats.
    Xu Y; Ren Y; Zhang J; Niu B; Liu M; Xu T; Zhang X; Shen J; Wang K; Cao Z
    Eur J Med Chem; 2024 Sep; 275():116565. PubMed ID: 38878518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptor antagonists: Structural exploration to target the A
    Poli D; Falsini M; Varano F; Betti M; Varani K; Vincenzi F; Pugliese AM; Pedata F; Dal Ben D; Thomas A; Palchetti I; Bettazzi F; Catarzi D; Colotta V
    Eur J Med Chem; 2017 Jan; 125():611-628. PubMed ID: 27721147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and c-Src inhibitory activity of imidazo[1,5-a]pyrazine derivatives as an agent for treatment of acute ischemic stroke.
    Mukaiyama H; Nishimura T; Kobayashi S; Ozawa T; Kamada N; Komatsu Y; Kikuchi S; Oonota H; Kusama H
    Bioorg Med Chem; 2007 Jan; 15(2):868-85. PubMed ID: 17095233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel pyrazolo-tetrahydropyridines as potent orexin receptor antagonists.
    Sifferlen T; Boss C; Cottreel E; Koberstein R; Gude M; Aissaoui H; Weller T; Gatfield J; Brisbare-Roch C; Jenck F
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1539-42. PubMed ID: 20144866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, antileishmanial activity and cytotoxicity of 2,3-diaryl- and 2,3,8-trisubstituted imidazo[1,2-a]pyrazines.
    Marchand P; Bazin MA; Pagniez F; Rivière G; Bodero L; Marhadour S; Nourrisson MR; Picot C; Ruchaud S; Bach S; Baratte B; Sauvain M; Pareja DC; Vaisberg AJ; Le Pape P
    Eur J Med Chem; 2015 Oct; 103():381-95. PubMed ID: 26383125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imidazo-pyrazine derivatives as potent CXCR3 antagonists.
    Du X; Gustin DJ; Chen X; Duquette J; McGee LR; Wang Z; Ebsworth K; Henne K; Lemon B; Ma J; Miao S; Sabalan E; Sullivan TJ; Tonn G; Collins TL; Medina JC
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5200-4. PubMed ID: 19631529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs).
    Mercer SP; Roecker AJ; Garson S; Reiss DR; Meacham Harrell C; Murphy KL; Bruno JG; Bednar RA; Lemaire W; Cui D; Cabalu TD; Tang C; Prueksaritanont T; Hartman GD; Young SD; Winrow CJ; Renger JJ; Coleman PJ
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6620-4. PubMed ID: 24215892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists.
    Boström J; Berggren K; Elebring T; Greasley PJ; Wilstermann M
    Bioorg Med Chem; 2007 Jun; 15(12):4077-84. PubMed ID: 17433696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and structure-activity relationships of a series of novel N-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists.
    Yoshida Y; Terauchi T; Naoe Y; Kazuta Y; Ozaki F; Beuckmann CT; Nakagawa M; Suzuki M; Kushida I; Takenaka O; Ueno T; Yonaga M
    Bioorg Med Chem; 2014 Nov; 22(21):6071-88. PubMed ID: 25267004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
    Belanger DB; Curran PJ; Hruza A; Voigt J; Meng Z; Mandal AK; Siddiqui MA; Basso AD; Gray K
    Bioorg Med Chem Lett; 2010 Sep; 20(17):5170-4. PubMed ID: 20674350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imidazo[1,2-a]pyrazine, Imidazo[1,5-a]quinoxaline and Pyrazolo[1,5-a]quinoxaline derivatives as IKK1 and IKK2 inhibitors.
    Patinote C; Bou Karroum N; Moarbess G; Deleuze-Masquefa C; Hadj-Kaddour K; Cuq P; Diab-Assaf M; Kassab I; Bonnet PA
    Eur J Med Chem; 2017 Sep; 138():909-919. PubMed ID: 28750313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.
    Robarge KD; Lee W; Eigenbrot C; Ultsch M; Wiesmann C; Heald R; Price S; Hewitt J; Jackson P; Savy P; Burton B; Choo EF; Pang J; Boggs J; Yang A; Yang X; Baumgardner M
    Bioorg Med Chem Lett; 2014 Oct; 24(19):4714-4723. PubMed ID: 25193232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclopropyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydroimid azo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, part 1.
    Malancona S; Altamura S; Filocamo G; Kinzel O; Hernando JI; Rowley M; Scarpelli R; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4422-8. PubMed ID: 21737272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclo- propyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydro-imidazo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, part 2.
    Kinzel O; Alfieri A; Altamura S; Brunetti M; Bufali S; Colaceci F; Ferrigno F; Filocamo G; Fonsi M; Gallinari P; Malancona S; Hernando JI; Monteagudo E; Orsale MV; Palumbi MC; Pucci V; Rowley M; Sasso R; Scarpelli R; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4429-35. PubMed ID: 21737263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.